Cathelicidin (LL-37) vs Magainin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
LL-37 is the sole human cathelicidin antimicrobial peptide, derived by proteolytic cleavage of the 18 kDa precursor hCAP18 (encoded by the CAMP gene). It is produced by neutrophils, epithelial cells of the skin, gut, and airways, and mast cells....
Calculate Cathelicidin (LL-37) dose →Magainins are cationic, alpha-helical antimicrobial peptides (AMPs) isolated from the skin of the African clawed frog Xenopus laevis by Michael Zasloff in 1987. They are among the founding members of the frog skin AMP family and established the concept of innate immune peptide de...
Calculate Magainin dose →| Parameter | Cathelicidin (LL-37) | Magainin |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Clinical Research | Clinical (topical) |
| Half-Life | < 10 min (plasma) | Minutes (plasma); hours (topical) |
| Typical Dose | Research: 1-100 ug/mL (topical) | Pexiganan cream 0.8% |
| Frequency | Varies by application | Twice daily (topical) |
| Route | Endogenous; topical/inhalation (research) | Topical (clinical), IV (research) |
| FDA Status | No approval (clinical trials ongoing) | Under review (pexiganan) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.